Eisai R&d Management Co., Ltd.

Ucl Business Plc

Other

Jared Spidel

Earl Albone

Luigi Grasso

James Bradford Kline

Kenzo Muramoto

Toshio Imai

Yoshimasa Sakamoto

Miyuki Nishimura

Tatsuo Horizoe

Tetsu Kawano

Kishan Agarwala

Shigeru Akasofu

Malcolm Ian Roberts

Yutaka Hashizume

James Martin Staddon

Hettihewage Alfred Rohan De Silva

Hirofumi Aoyagi

Brad Kline

Provided herein are conjugated immunoglobulins and methods for generating conjugated immunoglobulins using a microbial transglutaminase.

C-terminal lysine conjugated immunoglobulins

Lysine conjugated immunoglobulins

Provided herein are antibodies that specifically bind Tau and methods of using the same.

Anti-Tau antibodies and uses thereof

Antibodies, antigen-binding fragments, and conjugates (e.g., antibody-drug conjugates such as those comprising eribulin) thereof that bind to mesothelin are disclosed. The disclosure further relates to methods and compositions for use in the treatment of cancer by administering the compositions provided herein.

Eribulin antibody-drug conjugates and methods of use

Provided herein are methods for generating conjugated immunoglobulins, the method comprising: decapping a cysteine at amino acid position 80 ('Cys80') in a light chain variable region of an immunoglobulin, wherein the immunoglobulin comprises a heavy chain variable region and the light chain variable region; and conjugating a thiol-reactive compound to the Cys80, wherein the thiol-reactive compound comprises a thiol-reactive group. Antigen-binding molecules and methods for generating the same, immunoglobulins as well as nucleic acid molecules encoding the immunoglobulins and host cells comprising the nucleic acid molecules, conjugated immunoglobulins, and light chain variable regions for use in a conjugated immunoglobulin are also provided.

Cys80 conjugated immunoglobulins

Anti-tau antibodies and uses thereof

CYS80 conjugated immunoglobulins

The present invention relates to novel humanized, chimeric and murine antibodies that have binding specificity for the human CC chemokine ligand 20 (CCL20). The present invention further relates to heavy chains and light chains of said antibodies. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a heavy chain and/or a light chain of said antibodies, and to a method of preparing said antibodies. The anti-CCL20 antibodies of the invention can be used in therapeutic applications to treat, for example, inflammatory and autoimmune disorders and cancer.

Neutralizing anti-CCL20 antibodies

Nucleic acids encoding neutralizing anti-CCL20 antibodies

Growing community of inventors

Downingtown, PA, United States of America

Jared Spidel